(MT Newswires) -- Sanofi (SNY) Chief Financial Officer Jean-Baptiste de Chatillion discusses fourth-quarter results as the drugmaker forecasts a slowdown in profit growth with generic competition ratcheting up for multiple sclerosis drug Aubagio. He speaks with Francine Lacqua on "Bloomberg Surveillance Early Edition."

Bloomberg videos